FindTrial
Sign In

A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned

A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221435
Enrollment
Unknown
Registered
2011-04-18
Start date
2011-04-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome (Percutaneous Coronary Intervention)

Interventions

investigational material(s) Generic name etc : Ticagrelor (AZD6140), Low Dose ASA INN of investigational material : Ticagrelor, Acetyl Salicylic Acid Therapeutic category code : 339 Other agents relat

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Provision of signed informed consent - Index event of non-ST or ST segment elevation ACS

Exclusion criteria

Exclusion criteria: - Index event is an acute complication of percutaneous coronary intervention - Patient has undergone Percutaneous Coronary Intervention (PCI) after the index event before the first dose of study treatment - Oral anticoagulation therapy that cannot be stopped - The conditions associated with increased risk of bradycardiac events

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026